‘Practice-Changing’ Interventional Cardiology Research Grabs ACC.26 Spotlight

Why It Matters

These findings validate AI‑based and non‑invasive coronary physiology as reliable alternatives to pressure wires, promising faster, safer cath‑lab workflows and broader guideline adoption. The data also reinforce the therapeutic value of CTO PCI, influencing treatment standards and reimbursement decisions.

Key Takeaways

• FFRangio matched wire outcomes in 2,000‑patient trial
• Procedure and fluoroscopy times reduced with AI‑based FFRangio
• Medtronic to acquire CathWorks for up to $585 million
• vFFR noninvasive showed equal one‑year event rates
• CTO PCI improved quality of life versus placebo

Pulse Analysis

The ACC.26 spotlight on AI‑enabled coronary physiology marks a turning point for interventional cardiology. By leveraging advanced algorithms, FFRangio delivers fractional flow reserve estimates directly from angiograms, eliminating the need for pressure wires. The ALL‑RISE trial’s near‑identical major adverse cardiovascular event rates—6.9% versus 7.1%—combined with markedly shorter procedure and fluoroscopy times, underscore a streamlined workflow that can reduce radiation exposure and contrast use. As Medtronic moves to acquire CathWorks for up to $585 million, the industry signals confidence that AI tools will become standard in cath labs worldwide.

Equally compelling is the FAST‑III trial, which evaluated vessel‑derived FFR (vFFR) from two routine angiograms. Enrolling over 2,000 patients across 37 European centers, the study found a 7.5% composite event rate for both vFFR‑guided and traditional wire‑guided strategies, confirming non‑inferiority. Beyond clinical equivalence, vFFR offers operational advantages: faster decision‑making, reduced contrast load, and lower radiation doses. These efficiencies resonate with hospitals seeking to improve throughput and patient safety while adhering to evolving guideline recommendations for physiology‑guided revascularization.

The ORBITA‑CTO trial adds another layer of evidence, demonstrating that chronic total occlusion PCI delivers statistically significant quality‑of‑life gains and angina relief without increasing mortality or myocardial infarction risk. Although the sample size was modest (50 patients), the placebo‑controlled design eliminates bias and reinforces the therapeutic legitimacy of CTO interventions. Collectively, these studies accelerate the shift toward physiology‑centric, minimally invasive cardiac care, shaping future reimbursement models, device development, and clinical practice patterns.